Industry News Sponsored by
Naturex's fiscal 2012 revenue and profit both surged as it continued to benefit from acquisitions it completed in 2011 and 2012 as well as its strong position in emerging markets.
The company's fiscal 2012 revenue rose 18.2%, or 11.9% at constant exchange rates, to €299.8 million. Results included full-year contributions from the four companies Naturex acquired between the 2011 fourth quarter and the end of the 2012 third quarter (Burgundy in France and Spain, Pektowin in Poland, Valentine in India and DBS in the U.S.), which accounted for about 7% of the group's annual revenue.
Net income for the full year surged 46.8% to €22.9 million from €15.6 million a year earlier. The group benefited from its positions in active mature markets, despite a difficult economic environment in Europe, and in faster growing emerging markets which accounted for 17.7% of the annual revenue.
Naturex also said it booked positive operational drivers for the period consistent with its revenue growth despite expenses the group incurred related to measures adopted to restructure operations due to its rapid development over the past three years, and the short-term dilutive effect of some of its acquisitions.